Surprises of genetic engineering
Nina Raben(APT Therapeutics (United States)), Paul H. Plötz(National Institutes of Health), Alexander V. Skurat(National Institute of Arthritis and Musculoskeletal and Skin Diseases), Olimpia Musumeci(Nationwide Children's Hospital), E. Lee(National Institute of Arthritis and Musculoskeletal and Skin Diseases), Sara Shanske(Columbia University), Peter J. Roach(University of Kentucky), S. DiMauro(Columbia University), M. J. Danon(Hennepin County Medical Center), Nina Lu(National Institute of Arthritis and Musculoskeletal and Skin Diseases), John C. Lawrence(University of Virginia), L. Shliselfeld(National Institute of Arthritis and Musculoskeletal and Skin Diseases)
Cited by 105
Related Papers
Therapy of Lupus Nephritis
|New England Journal of Medicine|1986|1.2k
A New Approach to the Classification of Idiopathic Inflammatory Myopathy
|Medicine|1991|974
Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease)
|Nature|2000|941
Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene
|Nature Genetics|1999|571
Lipin 1 is an inducible amplifier of the hepatic PGC-1α/PPARα regulatory pathway
|Cell Metabolism|2006|561